-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Odyssey Therapeutics, Raises Price Target to $29

Benzinga·08/07/2026 16:15:47
Listen to the news
JP Morgan analyst Brian Cheng maintains Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight and raises the price target from $26 to $29.